Work

Molecular mechanisms and clinical tapering strategies for Janus kinase inhibitor relapse in inflammatory dermatoses

Year: 2026

Type: article

Abstract: Janus kinase (JAK) inhibitors have revolutionized the management of inflammatory dermatoses over recent decades; however, discontinuation is frequently associated with rapid disease recurrence, known as the “relapse” phenomenon, which complicates long-term disease control. Current evidence on the molecular pathophysiology of JAK inhibitor relapse emphasizes the unique pharmacodynamics of Type I inhibitors, which bind the kinase in its active conformation. This binding paradoxically stabilizes primed hyperphosphorylated JAKs and depletes Suppressors of Cytokine Signaling (SOCS) proteins, resulting in a “pharmacokinetic cliff” where pathway suppression is abruptly lost upon drug clearance. This review further categorizes clinical outcomes based on the velocity of the underlying pathology, contrasting the high relapse potential driven by rapid neural or cytotoxic reactivation in atopic dermatitis and alopecia areata against the slower, structural relapse seen in psoriasis. Finally, we propose evidence-based management frameworks, advocating for “slope of reduction” strategies that prioritize dose de-escalation over frequency extension to maintain steady-state suppression, providing a rational approach to safer deprescribing in clinical practice.

Source: Discover Immunity.

DOI: 10.1007/s44368-026-00038-7

Authors: Soroush Moradi, Amirhosein Rostami, Vesal Hasani, Parand Shariat Rad

Institutions: Kermanshah University of Medical Sciences, Kurdistan University of Medical Sciences

Language: English

Topic: Dermatology and Skin Diseases

Subfield: Dermatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $1,240